Israel
Anti-Hypertensive Drugs Market is expected to grow at an impressive rate during
the forecast period 2024-2028. The major factors
include increasing prevalence of hypertension due to
kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular
diseases due to which the prevalence of hypertension has observed a significant
rise over the past few years. Also, some drugs can induce hypertension in
patients with other diseases or disorders, which in turn, is expected to
promote the growth of the Israel Anti-Hypertensive Drugs market. According to World Health
Organization 2021, around 1.13 billion people across the world have
hypertension, of which two-third are living in low- and middle-income countries.
Hypertension is a preventable risk factor for atherosclerotic
diseases and ischemic heart diseases. This condition is marked by high pressure
of blood in the arteries. A number of patients maintain suboptimal blood
pressure control, despite the modern and effective antihypertensive drugs. Most
hypertensive patients require a combination of antihypertensive agents to
prevent heart stroke.
Additionally, rise in awareness related to complications
associated with hypertension is a major factor that fuels the growth of Israel anti-hypertensive drugs market. Moreover, the increase in geriatric population and
sedentary lifestyle also boosts the growth of the market. However, recent
patent expirations are anticipated to hinder the growth of the antihypertensive
market. Conversely, rise in research related to antihypertensive drugs is
expected to offer lucrative opportunities during the forecast period.
Increasing
Prevalence of Hypertension
The
increasing prevalence of hypertension is a major health concern across the
country. According to recent data, hypertension affects around 25% of the adult
population in Israel, with the prevalence increasing with age. One of the main
contributing factors to the increasing prevalence of hypertension in Israel is
the aging population. As people age, the risk of developing hypertension
increases. According to United Nations Economic Commission for Europe,
Israel has a rapidly aging population, with around 11% of the population aged
65 and over in 2021, and this demographic shift is expected to continue in the
coming years. Israel’s elderly population has some unique characteristics
because the country receives a steady stream of immigrants from 119 countries,
including many who are Holocaust survivors, representing a wide range of
ethnic, economic, health, educational and cultural differences.
Additionally,
another important factor contributing to the increasing prevalence of
hypertension in Israel is unhealthy lifestyle habits, such as a diet high in
salt and saturated fat, sedentary behavior, and smoking. These lifestyle
factors can increase the risk of hypertension, and are becoming increasingly
common in Israel, particularly among younger generations. Obesity, a major risk
factor for hypertension, is also on the rise in Israel. According to recent
data, the prevalence of obesity among adults in Israel has increased
significantly over the past decade, with around 27% of adults now classified as
obese. In response to the growing prevalence of hypertension in Israel,
healthcare providers are emphasizing the importance of early detection and
treatment. Lifestyle changes, such as diet and exercise, can help manage
hypertension, but many people also require medications to lower their blood
pressure. Ongoing research into new and more effective treatments for
hypertension is also essential in combating the growing prevalence of this
condition in Israel. This, in turn, increased the demand for Israel
anti-hypertensive drugs market in the forecast period.
Advancements in Drug Development
In April 2021, Radnor Biopharma developed a hormone targeting
treatment for hypertension.
The factors such as expiration of patent of multiple major drugs along with
side effects associated with the hypertension treatment and rise in the
availability of other non-pharmacological based therapy, will restrict the
growth of the anti-hypertensive drugs market. For Instance, In December
2021, AbbVie, the parent company of Allergan, lost the patent of its
anti-hypertensive drug, Bystolic (Nebivolol). Nebivolol
is a beta blocker used to treat high blood pressure and heart failure. These
factors propell the growth of Israel anti-hypertensive market.
Additionally,
in December 2021, Dr Reddy's Laboratories has launched Valsartan tablets, used
for treatment of high blood pressure and heart failure, in the United States
market. The Valsartan tablet is the generic therapeutic equivalent of Diovan,
approved by the United States Food and Drug Administration (USFDA). Similarly,
in November 2021, Otsuka Pharmaceutical Co., Ltd. reported that Novartis Pharma
K.K. (Novartis Pharma) has obtained approval in Japan for ENTREST 100 mg and
200 mg Tablets (generic name: sacubitril valsartan sodium hydrate) for the new
indication of hypertension. ENTRESTO is classified as a new class called an Angiotensin
Receptor Neprilysin Inhibitor (ARNI) with a novel mechanism of action that
simultaneously inhibits neprilysin (NEP) and the renin-angiotensin-aldosterone
system (RAAS). This approval is
Japan's first of an ARNI for the indication of hypertension.
Government
Initiatives and Funding
Israel
has been collaborating with United Nations to improve the lives of older
persons for many years and has worked closely with the United Nations Economic
Commission for Europe (UNECE) and its Task Force on Ageing and measuring institutional
populations for defining indicators and metrics. Certain other factors that
will boost the growth of the Israel anti-hypertensive drugs market include
growing initiatives by private and government organizations and rising
awareness about hypertension around the around. Few organizations have taken
initiatives to conduct a camp and check the blood pressure, making them aware
of various aspects of high blood pressure. It certainly adds to the growth of
Israel anti-hypertensive market.
The
growing awareness of the health risks associated with hypertension in Israel
has led to increased efforts to prevent and treat the condition. Public health
campaigns, educational programs, and outreach initiatives have been implemented
to raise awareness of the importance of managing blood pressure and reducing
the risk of hypertension-related health problems. Doctors and other healthcare
professionals have increasingly emphasized the importance of monitoring blood
pressure and treating hypertension early, to prevent long-term health
consequences. As a result, more people are being diagnosed with hypertension
and receiving treatment for the condition.
Public
health campaigns have also played a role in increasing awareness on the health
risks associated with hypertension in Israel. These campaigns aim to educate
the public about the importance of healthy lifestyle choices, such as diet and
exercise, in preventing hypertension. They also encourage people to get their
blood pressure checked regularly and to seek medical treatment if their blood
pressure is high. In addition to public health campaigns, educational programs
and outreach initiatives have been implemented to raise awareness of
hypertension in Israel. These programs focus on educating people about the risk
factors for hypertension, the importance of blood pressure monitoring, and the
benefits of early intervention and treatment.
The
Israel’s Ministry of Health has also taken steps to address the growing
prevalence of hypertension by implementing national guidelines for the
prevention, diagnosis, and treatment of the condition. These guidelines
emphasize the importance of lifestyle modifications, such as reducing salt
intake and increasing physical activity, as well as taking medications, when
necessary. Therefore, the growing awareness of the health risks associated with
hypertension in Israel has led to increased efforts to prevent and treat this
condition. The prevalence of hypertension and its associated health risks will
continue to decrease in Israel with continued efforts to educate public and
these factors propels the growth of Israel anti-hypertensive market.
Download Free Sample Report
Market Segmentation
Israel
Anti-Hypertensive Drugs Market can be segmented by therapeutic class, type, distribution channel,
and region. By therapeutic
class, the market can be segmented into Diuretics, ACE inhibitors, Angiotensin
Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers,
Renin Inhibitors, Vasodilators, Others. Based on type, the market can be segmented into Primary Hypertension and Secondary
Hypertension. In terms of Distribution Channel, the market can be segmented
into Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug
Stores.
Market Players
Pfizer Pharmaceuticals Israel
Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis
Israel Ltd, Boehringer Ingelheim Israel Ltd., Bristol-Myers Squibb Israel Ltd.,
Takeda Israel Inc., Teva Israel Ltd., Servier Israel Inc. etc. are some of the leading companies
operating in the Israel
anti-hypertensive drugs market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2022
|
|
Estimated
Year
|
2022
|
|
Forecast
Period
|
2023 – 2028
|
|
Quantitative
Units
|
Revenue
in USD Million, Volume Units and CAGR for 2018-2022 and 2023-2028
|
|
Report
coverage
|
Revenue
forecast, Volume forecast company share, competitive landscape, growth
factors, and trends
|
|
Segments
covered
|
Therapeutic
Class
Type
Distribution
Channel
Region
Company
|
|
Regional
scope
|
The
Mediterranean coastal plain, The Central Hills, The Jordan Rift Valley and
The Negev Desert
|
|
Key
companies profiled
|
Pfizer
Pharmaceuticals Israel Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc,
Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Boehringer Ingelheim
Israel Ltd., Bristol-Myers Squibb Israel Ltd., Takeda Israel Inc., Teva
Israel Ltd., Servier Israel Inc.
|
|
Customization
scope
|
10% free
report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel
through Email (We can also provide the editable version of the report in
PPT/Word format on special request)
|
Report Scope:
In this report, Israel Anti-Hypertensive Drugs Market has been segmented
into following categories, in addition to the industry trends which have also
been detailed below:
·
Israel
Anti-Hypertensive Drugs Market, By Therapeutic Class
o
Diuretics
o
ACE inhibitors
o
Angiotensin Receptor Blockers (ARBs)
o
Calcium Channel Blockers
o
Beta Adrenergic Blockers
o
Renin Inhibitors
o
Vasodilators
o
Others
·
Israel Anti-Hypertensive Drugs Market, By Type
o
Primary Hypertension
o
Secondary Hypertension
·
Israel Anti-Hypertensive Drugs Market, By Distribution Channel
o
Retail Pharmacy
o
Hospital Pharmacy
o
E-commerce Websites
o
Online Drug Stores
·
Israel Anti-Hypertensive Drugs Market, By Region:
o The Mediterranean coastal plain
o The Central Hills
o The Jordan Rift Valley
o The Negev Desert
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in Israel Anti-Hypertensive Drugs Market
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
Detailed analysis and
profiling of additional market players (up to five).Israel Anti-Hypertensive Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]